Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7423161
Reference Type
Journal Article
Title
Neurosteroids in Alcohol and Substance Use
Author(s)
Ginsburg, BC; Gerak, LR; Mcmahon, LR; Roache, JD; ,
Year
2008
Publisher
Springer Netherlands
Location
Dordrecht
Book Title
Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders
Page Numbers
509-538
DOI
10.1007/978-1-4020-6854-6_25
URL
http://link.springer.com/10.1007/978-1-4020-6854-6_25
Exit
Abstract
Allopregnanolone and related neurosteroids share effects with ethanol at several critical targets. Though data are equivocal in humans, acute administration of ethanol (and several other drugs of abuse) increases brain and plasma levels of allopregnanolone in animals. Evidence exists suggesting that this effect of ethanol is mediated via the peripheral or mitochondrial benzodiazepine receptor (PBR). PBR activation can stimulate neurosteroid synthesis and results in anxiolytic effects similar to ethanol, benzodiazepines, and neurosteroids. Further, finasteride, an inhibitor of neurosteroidogenesis, blunts some effects of ethanol in animals and humans. Thus, neurosteroids may modulate or mediate effects of ethanol, benzodiazepines, and barbiturates. Like ethanol and allopregnanolone, benzodiazepines and barbiturates are positive GABA-A receptor modulators. Accordingly, neurosteroids share discriminative stimulus properties with ethanol, benzodiazepines, and barbiturates. Allopregnanolone and related neurosteroids are self-administered by animals, similar to ethanol and other abused drugs. A role for neurosteroids in ethanol tolerance and withdrawal has also emerged, as rodents undergoing ethanol withdrawal are sensitized to neurosteroid effects and alcoholics in withdrawal display reduced allopregnanolone levels. While symmetrical cross tolerance develops between ethanol and benzodiazepines, asymmetrical cross tolerance develops between neurosteroids and benzodiazepines or ethanol, which could be exploited to help treat ethanol, benzodiazepine or barbiturate dependence and withdrawal.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity